Clinical Research Directory
Browse clinical research sites, groups, and studies.
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
Sponsor: Qingyuan Zhan
Summary
Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and alleviating the burden on families and society. To address this medical challenge, our institution is conducting a study aimed at lowering PJP-related mortality. Specifically, we are performing an adaptive, randomized, open-label controlled trial in patients with severe PJP. The primary objective of this study is to scientifically evaluate the efficacy and safety of adjunctive corticosteroids at different dosages, in addition to early standard supportive care, for reducing mortality in severe PJP
Official title: An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PJP) in Non-HIV Immunocompromised Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-09-08
Completion Date
2027-12-31
Last Updated
2025-09-09
Healthy Volunteers
No
Conditions
Interventions
Saline (0.9%, sterile, for infusion)
Saline for control
Low Dose Corticosteroids
Methylprednisolone 0.5mg/kg ivgtt qd
Moderate dose corticosteroids
Methylprednisolone 1.0mg/kg ivgtt qd